## **What is HCPCS code Q5106?**
HCPCS code Q5106 is used for injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units. This procedure code specifically covers the biosimilar version of recombinant human erythropoietin manufactured as Retacrit, designed for patients who do not have end-stage renal disease (ESRD). The value code Q5106 distinguishes this biosimilar formulation from reference products and other erythropoiesis-stimulating agents (ESAs) used in clinical practice.
Epoetin alfa-epbx biosimilar (Retacrit) functions as a hematopoietic growth factor that stimulates red blood cell production in the bone marrow. This injection epoetin alfa-epbx provides an effective treatment option for patients experiencing symptomatic anemia related to various chronic diseases classified under multiple medical conditions, such as unspecified chronic kidney disease, etc.
Primary indications include cancer chemotherapy-induced anemia in patients receiving concomitant myelosuppressive chemotherapy for non-myeloid malignancy, chronic kidney disease patients not requiring dialysis, chronic renal failure, and HIV-infected patients receiving antineoplastic chemotherapy.
## **Documentation requirements**
Comprehensive documentation is essential for demonstrating medical necessity and ensuring appropriate reimbursement for Q5106 billing:
- Documentation must clearly establish the underlying condition causing anemia and demonstrate that the patient meets criteria for ESA treatment.
- Initial therapy documentation must include baseline hemoglobin levels, serum ferritin, transferrin saturation, and other relevant laboratory parameters.
- Documentation must confirm the absence of contraindications, including uncontrolled hypertension and a history of severe cutaneous reactions to ESAs.
- For cancer patients, the record should document that the goal is correcting anemia to avoid allogeneic blood transfusions rather than achieving supranormal hemoglobin levels.
## **Billing requirements**
Medicare coverage for Q5106 follows established criteria for ESAs in non-ESRD patients. Q5106 billing requires accurate reporting of units administered. Since the code represents 1000 units, providers must calculate the total units given and bill accordingly. For example, a 4000-unit dose would be billed as four units of Q5106. Dose adjustments based on hemoglobin response should be properly documented and reflected in subsequent billing.
Claims should include appropriate place of service codes reflecting where the injection was administered. Office-based administration requires different coding than hospital outpatient or infusion center delivery. Proper documentation of administration route, dose, and patient monitoring supports successful reimbursement.
## **Other relevant codes**
Healthcare practitioners managing anemia with ESAs should be familiar with related coding options for comprehensive patient care:
- **J0881** - Injection, darbepoetin alfa, 1 microgram (non-ESRD use)
- **J0882** - Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)
- **Q4081** - Injection, epoetin alfa, 100 units (for ESRD on dialysis)
- **Q5105** - Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units
Frequently asked questions
